Search results for "SARS-CoV-2"

showing 10 items of 1204 documents

Managing cancer patients during the COVID-19 pandemic:an ESMO multidisciplinary expert consensus

2020

We established an international consortium to review and discuss relevant clinical evidence in order to develop expert consensus statements related to cancer management during the severe acute respiratory syndrome coronavirus 2-related disease (COVID-19) pandemic. The steering committee prepared 10 working packages addressing significant clinical questions from diagnosis to surgery. During a virtual consensus meeting of 62 global experts and one patient advocate, led by the European Society for Medical Oncology, statements were discussed, amended and voted upon. When consensus could not be reached, the panel revised statements until a consensus was reached. Overall, the expert panel agreed …

0301 basic medicinemedicine.medical_specialtyConsensusCoronavirus disease 2019 (COVID-19)Settore MED/18 - CHIRURGIA GENERALEPneumonia ViraleducationDiseaseMedical OncologyReal-Time Polymerase Chain ReactionSpecial Article03 medical and health sciencesBetacoronavirus0302 clinical medicineMultidisciplinary approachNeoplasmsPandemicGranulocyte Colony-Stimulating FactorMedicineHumansDisease management (health)PandemicsSocieties Medicalbusiness.industrySARS-CoV-2Expert consensusCOVID-19Disease ManagementcovidHematologyTelemedicineEurope030104 developmental biologyOncology030220 oncology & carcinogenesisFamily medicineCancer managementSevere acute respiratory syndrome coronavirusbusinessCoronavirus InfectionsT-Lymphocytes Cytotoxic
researchProduct

The role of immunogenetics in covid‐19

2021

Coronavirus disease 2019 (COVID-19) is induced by SARS-CoV-2 and may arise as a variety of clinical manifestations, ranging from an asymptomatic condition to a life-threatening disease associated with cytokine storm, multiorgan and respiratory failure. The molecular mechanism behind such variability is still under investigation. Several pieces of experimental evidence suggest that genetic variants influencing the onset, maintenance and resolution of the immune response may be fundamental in predicting the evolution of the disease. The identification of genetic variants behind immune system reactivity and function in COVID-19 may help in the elaboration of personalized therapeutic strategies…

0301 basic medicinemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)ReviewDiseaseImmunogeneticsHuman leukocyte antigenSeverity of Illness IndexCatalysisSARS‐CoV‐2ABO Blood-Group SystemInorganic Chemistrylcsh:Chemistry03 medical and health sciences0302 clinical medicineCOVID‐19HLA AntigensmedicineImmunogeneticsHumansGenetic Predisposition to DiseaseGenetic variabilityPhysical and Theoretical ChemistryIntensive care medicineMolecular Biologylcsh:QH301-705.5SpectroscopyAB0business.industrySARS-CoV-2Organic ChemistryImmunityCOVID-19General MedicineImmunosenescencemedicine.disease3. Good healthComputer Science ApplicationsKIRHLA030104 developmental biologylcsh:Biology (General)lcsh:QD1-999030220 oncology & carcinogenesisIdentification (biology)Disease SusceptibilityCytokine stormbusiness
researchProduct

What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects

2020

Within the COVID-19 pandemic context, the WHO has proposed a list of medicines to treat patients with severe acute respiratory syndrome (SARS-CoV-2). An analysis of their ocular side effects was performed. Only chloroquine and hydroxychloroquine were found to have an ocular impact in the medium and long-term. Detailed search strategies were performed in EMBASE, MEDLINE, SCOPUS and WOS Core Collection. Additionally, the worldwide ongoing clinical trials including chloroquine or hydroxychloroquine were evaluated, and their proposals of drug administration and exclusion criteria analyzed. In general, high maximum cumulative doses of chloroquine or hydroxychloroquine are being used for a short…

0301 basic medicinemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsCoronavirus disease 2019 (COVID-19)Health PersonnelRetinal pathology / researchSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Context (language use)medicine.disease_causeRetinaAntimalarials03 medical and health sciences0302 clinical medicineRetinal DiseasesChloroquineInternal medicinePandemicmedicineHumansRETINARetina – medical therapiesCoronavirusPharmacologyOphthalmologistsSARS-CoV-2business.industryCOVID-19ChloroquineHydroxychloroquineGeneral MedicineSystemic drug retinal ToxicityTechniques of retinal examinationCOVID-19 Drug TreatmentCoronavirusClinical trialOphthalmology030104 developmental biologyCaregiversMedicina Preventiva y Salud Pública030221 ophthalmology & optometryHuman medicinebusinessHydroxychloroquinemedicine.drugEuropean journal of ophthalmology
researchProduct

Protective Effects of Statins Administration in European and North American Patients Infected with COVID-19: A Meta-Analysis

2021

AbstractSevere acute respiratory syndrome coronavirus 2 has spread rapidly throughout the world, becoming an overwhelming global health emergency. The array of injuries caused by this virus is broad and not limited to the respiratory system, but encompassing also extensive endothelial and systemic tissue damage. Since statins effectively improve endothelial function, these drugs may have beneficial effects in patients with coronavirus disease 2019 (COVID-19). Therefore, this investigation aimed to provide an updated overview on the interplay between statins and COVID-19, with particular focus on their potentially protective role against progression toward severe or critical illness and deat…

0301 basic medicinemedicine.medical_specialtyStatinmedicine.drug_class030204 cardiovascular system & hematologyStatins COVID-19 Meta-analysislaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineAdjuvant therapyGlobal healthHumansSARS-CoV-2business.industryStatinsCOVID-19HematologyOdds ratioUnited StatesConfidence intervalCOVID-19 Drug TreatmentReview articleEuropeHospitalizationMeta-analysis030104 developmental biologyMeta-analysisHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessSeminars in Thrombosis and Hemostasis
researchProduct

Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19☆

2020

Pneumonia caused by coronavirus, which originated in Wuhan, China, in late 2019, has been spread around the world already becoming a pandemic. Unfortunately, there is not yet a specific vaccine or effective antiviral drug for treating COVID-19. Many of these patients deteriorate rapidly and require intubation and are mechanically ventilated, which is causing the collapse of the health system in many countries due to lack of ventilators and intensive care beds. In this document we review two simple adjuvant therapies to administer, without side effects, and low cost that could be useful for the treatment of acute severe coronavirus infection associated with acute respiratory syndrome (SARS-C…

0301 basic medicinemedicine.medical_specialtyVitamina Cmedicine.drug_classLung injurymedicine.disease_causeArticle03 medical and health sciences0302 clinical medicineOzoneIntensive caremedicineAdjuvant therapyVitamin CIntensive care medicineOzonoCoronavirusbusiness.industrySARS-CoV-2COVID-19030208 emergency & critical care medicineGeneral MedicineAscorbic acidmedicine.diseaseClinical trialPneumonia030104 developmental biologyAntiviral drugbusinessRevista Española de Anestesiología y Reanimación (English Edition)
researchProduct

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors. Prospective analysis from a multicentre observational tri…

2020

Background:This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events.Patients and methods:Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared …

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentimmune-checkpoint inhibitorsinfluenza-like illnesslcsh:RC254-28203 medical and health sciences0302 clinical medicineCancer immunotherapyInternal medicineMedicineProspective cohort studyCancer stagingOriginal ResearchInfluenza-like illnessbusiness.industrySARS-CoV-2virus diseasesCOVID-19Immunotherapycancer patients; COVID-19; immune-checkpoint inhibitors; influenza-like illness; SARS-CoV-2lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseComorbidityVaccination030104 developmental biologyOncology030220 oncology & carcinogenesisObservational studybusinesscancer patients
researchProduct

Does Evidence Exist to Blunt Inflammatory Response by Nutraceutical Supplementation during COVID-19 Pandemic? An Overview of Systematic Reviews of Vi…

2021

More than one year has passed since the first cases of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS)-CoV-2 coronavirus were reported in Wuhan (China), rapidly evolving into a global pandemic. This infectious disease has become a major public health challenge in the world. Unfortunately, to date, no specific antivirals have been proven to be effective against COVID-19, and although a few vaccines are available, the mortality rate is not decreasing but is still increasing. One therapeutic strategy has been focused on infection prevention and control measures. In this regard, the use of nutraceutical supports may play a role against some aspect of the i…

0301 basic medicinemedicine.medical_specialtyoverviewvitamin Clcsh:TX341-641vitamin DmelatoninAscorbic AcidCochrane LibraryMelatonin03 medical and health sciences0302 clinical medicineNutraceuticalImmune systemMeta-Analysis as Topicsystematic reviewInternal medicineVitamin D and neurologyMedicineInfection controlHumans030212 general & internal medicinenutraceuticalsNutrition and DieteticsVitamin Cbusiness.industrySARS-CoV-2zincCOVID-19VitaminsTrace ElementsCOVID-19 Drug Treatment030104 developmental biologySystematic reviewC-Reactive ProteininflammationImmune SystemDietary Supplementsbusinesslcsh:Nutrition. Foods and food supplyFood Sciencemedicine.drug
researchProduct

Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection

2021

Apart from prevention using vaccinations, the management options for COVID-19 remain limited. In retrospective cohort studies, use of famotidine, a specific oral H2 receptor antagonist (antihistamine), has been associated with reduced risk of intubation and death in patients hospitalized with COVID-19. In a case series, nonhospitalized patients with COVID-19 experienced rapid symptom resolution after taking famotidine, but the molecular basis of these observations remains elusive. Here we show using biochemical, cellular, and functional assays that famotidine has no effect on viral replication or viral protease activity. However, famotidine can affect histamine-induced signaling processes i…

0301 basic medicinemedicine.medical_treatmentPharmacologyVirus ReplicationBiochemistrychemistry.chemical_compoundChemokine CCL2Coronavirus 3C ProteasesResearch ArticlesToll-like receptorbiologyNF-kappa BFamotidineMolecular Docking SimulationCytokine release syndromeCytokinemedicine.symptomSignal transductionHistaminemedicine.drugProtein BindingSignal TransductionHistamine AntagonistsInflammation03 medical and health sciencesToll-like receptormedicineHumansInterleukin 6Molecular BiologyBinding Sites030102 biochemistry & molecular biologybusiness.industryInterleukin-6SARS-CoV-2Cell Biologymedicine.diseasehistamineToll-Like Receptor 3Famotidine030104 developmental biologychemistryA549 CellsSARS-CoV2biology.proteinanti-viral signalingInterferon Regulatory Factor-3Caco-2 CellsbusinessHeLa Cells
researchProduct

De Novo Genome Assembly of the Raccoon Dog (Nyctereutes Procyonoides)

2021

The raccoon dog, Nyctereutes procyonoides (NCBI Taxonomy ID: 34880, Figure 1a) belongs to the family Canidae, with foxes (genus Vulpes) being their closest relatives (Lindblad-Toh et al., 2005; Sun et al., 2019). Its original distribution in East Asia ranges from south-eastern Siberia to northern Vietnam and the Japanese islands. In the early 20th century, the raccoon dog was introduced into Western Russia for fur breeding and hunting purposes, which led to its widespread establishment in many European countries, Figure 1b. Together with the raccoon (Procyon lotor), it is now listed in Europe as an invasive species of Union concern (Regulation (EU) No. 1143/2014) and member states are requi…

0301 basic medicinepopulation genomicsRange (biology)ZoologyB chromosomeQH426-470GenomePopulation genomics03 medical and health sciences0302 clinical medicineddc:590Data ReportGeneticsraccoon dog (nyctereutes procyonoides)IUCN Red Listmedia_common.cataloged_instanceGenetics (clinical)Syntenymedia_commonB chromosomebiologySARS-CoV-2sequencebiology.organism_classificationgenome assembly and annotationanimalsCanis lupus familiaris030104 developmental biology030220 oncology & carcinogenesisrangeMolecular MedicinecarnivoraNyctereutes procyonoides
researchProduct

Application of a portable instrument for rapid and reliable detection of SARS-CoV-2 infection in any environment

2020

Abstract The ongoing outbreak of the novel coronavirus (SARS‐CoV‐2) infection is creating serious challenges for health laboratories that seek to identify viral infections as early as possible, optimally at the earliest appearance of symptom. Indeed, there is urgent need to develop and deploy robust diagnostic methodologies not only to use in health laboratory environments but also directly in places where humans circulate and spread the virus such as airports, trains, boats, and any public aggregation places. The success of a reliable and sensitive asymptomatic diagnosis relies on the identification and measurement of informative biomarkers from human host and virus in a rapid, sensitive, …

0301 basic medicineportableSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralImmunologycoronavirusBiologymedicine.disease_causeSensitivity and SpecificityDisease OutbreaksWorkflowBetacoronavirus03 medical and health sciencesCOVID-19 Testing0302 clinical medicinePandemicmedicineAnimalsHumansMass ScreeninginstrumentImmunology and AllergyBiomarker discoveryAsymptomatic InfectionsPandemicsdeviceMass screeningCoronavirusInvited ReviewClinical Laboratory TechniquesSARS-CoV-2COVID-19Reproducibility of ResultsClinical Laboratory Servicescoronavirus; device; instrument; portable; SARS-CoV-2 detection; Animals; Asymptomatic Infections; Betacoronavirus; Biomarkers; Clinical Laboratory Services; Clinical Laboratory Techniques; Coronavirus Infections; Disease Outbreaks; Humans; Mass Screening; Pandemics; Pneumonia Viral; Reproducibility of Results; Sensitivity and Specificity; WorkflowIdentification (information)030104 developmental biologyWorkflowRisk analysis (engineering)SARS‐CoV‐2 detectionCoronavirus InfectionsHost (network)Biomarkers030215 immunology
researchProduct